The Anesthesia Playbook for Psychedelic Medicine with Owen Scott Muir, MD, DFAACAP, co-founder & Chief Scientific Officer, Radial
On this episode of Inside the Revival, a Psylencia Media production on Healthcare NOW Radio, host Jim Tate, President of EMR Advocate, talks with Owen Scott Muir, MD, DFAACAP, co-founder and Chief Scientific Officer of Radial. The question: what will it actually take to scale FDA-approved psychedelic medicine in the United States?
A self-described loyal skeptic who has never taken a psychedelic, Dr. Muir argues that access depends on aligning reimbursement with delivery. That means REMS-defined staffing, all-day treatment models proven in accelerated TMS and Spravato (esketamine) clinics, insurance coverage over cash pay, and realistic drug pricing benchmarks.
The conversation covers:
Tthe Lykos (now Resilient Pharmaceuticals) MDMA resubmission
Compass Pathways' COMP360 psilocybin NDA
Lessons from Australia's and Oregon's programs
The GLP-1 label-expansion playbook
A prior authorization strategy for the first psychedelic prescriptions, which our show notes test against URAC, NCQA, and CMS standards
Essential listening for health system, health plan, and behavioral health leaders preparing for psychedelic-assisted treatment.
26 Aug 2026
The Psychedelic Moon Landing: Inside the World's First Legal Extended-State DMT Research Center
What does it look like when a decade of ketamine therapy experience, a government-issued psychedelic research license in the Caribbean, and the world's most advanced DMT infusion protocol converge in a single clinical operation? On this episode of Inside the Revival, host Jim Tate sits down with Charles N. Patty, co-founder and Chief Visionary Officer of Elusis Mind, operating in Saint Vincent and the Grenadines, to explore extended-state DMT (DMTx) research as it is actually being practiced, not theorized.
Patty traces the scientific lineage of DMTX from Dr. Rick Strassman's DEA-approved human trials at the University of New Mexico in the 1990s through Dr. Andrew Gallimore and Dr. Chris Timmermann's landmark pilot study at Imperial College London, and into Elusis Mind's applied research protocol, i.e., 150-plus sessions to date, with 78% of participants reporting entity contact experiences. He details the center's tiered immersion programs (4-day/3-night Essential and 6-day/5-night Complete), its rigorous screening infrastructure, its SSRI and contraindication protocols, and its use of AI-assisted journey report analysis to map the DMT state. He also locates DMTX within the fast-evolving U.S. regulatory landscape, including President Trump's April 2026 executive order directing $50 million toward psychedelic research and makes the case for DMT and ketamine as the molecules most suited to scalable clinical application.
7 Aug 2026
The Age of the Sage: Psilocybin, Women Over 60, and the Medicine That Meets Them Where They Are
The Age of the Sage: Psilocybin, Women Over 60, and the Medicine That Meets Them Where They Are by PsylenciaMedia
Contact PsylenciaMedia
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of PsylenciaMedia?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
